Stock Incubator

[dalcindo]

Re: PSGI - 9-Month, DAILY Chart:

PSGI - 9-Mo., Daily Chart - 18 NOV 09


- Dalcindo

[dalcindo]

Re: BNX - 6-Mo., Daily Chart:

Showing speculative trendlines that seem to influence price:

BNX - 6-Mo., Daily Chart


- Dalcindo

[dalcindo]

Re; PDMI - Channel Validation:

15-MINUTE Chart:
RSI remains in its 40-80 BULLISH range per 15-minute chart. Although the bearish channel is getting further validation in this 15-minute chart, look for support at the 0.0040/0.00425 range, corresponding to lower border of the speculative bullish channel.

Overall, RSI failing the 70-level in DAILY chart is of particular concern, but not substantiated considering recent run - Profit has to first clear the table, folks.

PDMI - 9-Day, 15-MINUTE Chart:


PDMI - 12-Month, DAILY Chart:


36-Month, WEEKLY Chart:


60-Month, MONTHLY Chart:


- Dalcindo

[dalcindo]

re: IYR, Fin's Relative Strength Chart:

Topping so near to the support line suggests to me that it will likely try to break below it, IMHO.

In the chart below, it is getting clear that the Fin's (IYF, XLF, FAS) are loosing strength, when compared to the $SPX:



- Dalcindo

----------------------------------------------------------------
Message In Reply To 6979 - Options Wonderland Board:
~IYR~
screenshot#079

[dalcindo]

Re: UNG - Weekly Chart:

Significant positive divergences have formed in RSI, as well as secondary indicators. Not shown here are early reversal patterns in the daily chart:

UNG - 36-Month, WEEKLY Chart:


- Dalcindo

[dalcindo]

Re: BIDU - Closed at major historical resistance; remains BEARISH:

Bearish signs persist in:
1 - RSI lower highs;
2 - Negative divergence with RSI per today's daily close (16 NOV 09);
3 - Continued decline in volume at current resistance levels
4 - Lower highs or topping of secondary indicators;
5 - 3rd validation of Fibonacci's grid at zero-level retracement by day's close;
6 - ChiOsc negative divergence against A/D line and OBV.

Overall - Persistent bearish divergences and oversold indicators at current historical high suggest heavy resistance and higher probability for decline than continued rally:

12-month, Daily Chart:


- Dalcindo

[dalcindo]

Re: PDMI - 15-Minute Chart - Still pretty BULLISH:

See links for daily, weekly and monthly charts; patterns remain consistent with bullish run continuation:



- Dalcindo

[dalcindo]

Re: PDMI - Monthly Chart:



- Dalcindo

[dalcindo]

Re: PDMI - Weekly Chart:



- Dalcindo

[dalcindo]

Re: PDMI - Daily Chart:



- Dalcindo

[dalcindo]

Re: PDMI - Confirmed BULLISH reversal

Since two related postings ago (on my stock incubator) when the 12-month daily chart provided patterns typical of an early bullish reversals, PDMI's 14-daily RSI has confirmed its BULLISH reversal when price climbed from 0.0018 to a 0.0041 close, an impressive 127.8% rally.

If this rally is to continue and validate the upper border of the speculative bullish channel (green: "(s)UTC - 29 OCT 09"), then it would overcome two technical hurdles: first, it would convert from the speculative bearish channel ("(s)DTC - 29 OCT 09) to the bullish one, which is usually expected to occur after some significant resistance. Second, it would achieve a new 3-month high once it breaks through the mid-OCT 09 high of 0.0088.

These two technical hurdles are significant, and only a sustained bullish momentum could achieve this if fueled by some unusual underlying fundamentals (e.g.: buy-out, up-listing, significant FDA approval). I would look at RSI crossing over the 70-line for a measure of such moment, IMHO.

A caveat here: The steepness of +DI suggests that the upward course is likely going to be incremental, lending further credence that above incremental scenario is far more likely to occur (i.e.: resistance at the upper border of the bearish channel, then resistance at the 52-week high) than a straight shot to the upper border of the speculative bullish channel.



- Dalcindo

[dalcindo]

Weekly Scans - Week of 16 NOV 09:


Bucking Bull:
ENMD EntreMed, Inc. NASD
MZEI Medizone Intl Inc. NASD
NLST Netlist Inc. NASD
VKNG Viking Systems, Inc. NASD
Count: 4

Bull Pop:
EOPI ECO2 Plastics, Inc. NASD
Count: 1

ROW x STO:
Count: 0


Happy trading week!

- Dalcindo

[read_this_n0w]

[dalcindo]

Watch List: GELYF, ITRO, STWG

- D.

[dalcindo]

Re: DOW and Fibonacci, $COMPQ, $NYA:

Lang,

Interestingly, check out the point where to which the DOW rallied and stopped: Exactly at the significant Fib extention = 161.8% (first chart below)

Looking at $SPX alone, the chart is pointing to some serious resistance overhead as well.

Now, adding the $NYA to the picture: its 144-weekly EMA is getting validated once more by way of overhead resistance; MACD is also adding some credence to the expectation of market rolling down soon - Could be a correction or a new leg down; time wil tell.


$INDU&p=W&yr=3&mn=0&dy=0&i=p31190924988&a=154030889&r=885">








- Dalcindo

[dalcindo]

Re: PDMI - Looking ready to run

Agreed with you Baggers, looks like PDMI is set up for a run. Looking forward to a new level:



- Dalcindo

[dalcindo]

Article, Re: BIDU - Google eyes China as Baidu fumbles

Source: http://www.reuters.com/article/ousivMolt/idUSTRE5A95HL20091110

Tue Nov 10, 2009 5:11pm EST

By Alexei Oreskovic and Melanie Lee - Analysis

SAN FRANCISCO/SHANGHAI (Reuters) - In 2005, China administered a spelling test that asked respondents to spell "Google" for a search market report: only 60 percent took the test and more than 20 percent got it wrong.



Four years later, Google Inc (GOOG.O: Quote, Profile, Research, Stock Buzz), whose whimsical name is synonymous with Internet search in much of the world, is still struggling for recognition in China, the world's largest Internet market by users where local rival Baidu Inc (BIDU.O: Quote, Profile, Research, Stock Buzz) dominates.

Yet, Baidu's switch to a new advertising system, Phoenix Nest, may be the catalyst that boosts Google's market share.

Last month Baidu warned investors it will lose customers and post lower revenue than expected in the upcoming quarters due to the switch.

Analysts say Google could capitalize on Baidu's disruption, but note that the U.S. company needs to more broadly revise its strategy and align itself with local companies to gain on its search rival in China.

"For whatever reason right now, the brand just doesn't have the same cachet (in China) that it has here," Broadpoint AmTech analyst Benjamin Schachter said of Google in China.

Revenue from China is just a fraction of Google's roughly $22 billion in annual, worldwide sales, analysts said. But the country's massive population and fast growth make it key to the future, particularly as growth slows in mature markets like the U.S., where Google already has a roughly 65 percent share.

Google has overtaken many of the other search companies in China, including Yahoo Inc (YHOO.O: Quote, Profile, Research, Stock Buzz), growing its share of China's 2 billion yuan ($293 million) search market to 31 percent in the third quarter. But Google has been unable to crack Baidu's share of the market, which stood at 64 percent share in the third quarter of 2009, according to Analysys International.

here

Change at Google's China business has already come at the top. In September, Google appointed its head of sales, John Liu, to take over former China chief Lee Kai Fu's business responsibilities.

Liu told local media in September that he intends to double Google's sales force in China in six months, although he was not more specific. Baidu already has a sales and customer service team of over 4,000.

Google has also beefed up its ranks of engineers with a focus on making the search engine better-suited toward Chinese language Web content. It was not immediately clear how many people Google employs in China.

At a recent roundtable discussion with reporters in Boston, CEO Eric Schmidt said the quality of Google's search results in China is now on par or better than the competition, in terms of speed and relevance, according to internal tests.

Still, some Chinese users say Baidu, whose name is taken from an ancient Chinese poem, has better contextualized search results. For example, typing in "Power Station" in a Google China search will give hits on what a power station is, whereas on Baidu, you get links to news articles and songs by the Taiwanese band Power Station.

MUSIC AND DEALS

The fundamental problem with Google in China could be as simple as that the company is not Chinese, analysts say.

The world's most populous nation only started liberalizing its economy in the 1980s and has traditionally favoured Chinese brands in its sensitive media sector because they are easier to police than their Western counterparts.

While some analysts maintain that China's thorny regulatory environment is a challenge for both Western and Chinese companies alike, local firms have operational advantages that let them react faster to market conditions.

"Local companies can execute on crucial strategy and tactics without having to get the go-ahead from headquarters across the Pacific," Kaiser Kuo, a China Internet commentator and the former director of digital strategy at Ogilvy China said in an email.

Google likes to boast that founders Larry Page and Sergey Brin still vet every new hire. But in overseas operations like China, that can mean a lack of autonomy that can create bottlenecks, said Sanford Bernstein analyst Jeff Lindsay.

The answer might lie in partnerships. In March Google struck a deal with Chinese music site Top100.cn to offer up to 1.1 million licensed songs through the Google search engine.

The deal addressed a fundamental shortcoming of Google's, whose policy of blocking access to pirated online music hurt its standing among China's music-obsessed Web surfers.

JMP Securities analyst Sameet Sinha said Google could buy a Chinese Web firm to boost its standing in China, though he noted that valuations are high.

"Everything is booming over there," said Sinha

(Reporting by Alexei Oreskovic and Melanie Lee, editing by Tiffany Wu and Derek Caney)


© Thomson Reuters 2009. All rights reserved. Users may download and print extracts of content from this website for their own personal and non-commercial use only. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters and its logo are registered trademarks or trademarks of the Thomson Reuters group of companies around the world.

Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

--------------------------------------------------------------

- Dalcindo

[dalcindo]

Re: GELYF - Weekly and Daily Chart:

Obviously a pretty bullish outlook for this stock - Will keep an eye on it.

Thank you Tony for all your fundamental background on this pup!

GELYF - 18-Mnth, Weekly Chart:



GELYF - 12-Month, Daily Chart:



- Dalcindo

[dalcindo]

Re: $USD: Monthly, Weekly, Daily Charts: RALLY!

As a follow-up and warning, in MONTHLY Chart #1, the $USD has finally reached the lower border of its bullish channel, which was drawn and validated multiple times since last SEP 2008.

Corresponding to this recent validation are:
1 - Tapering of CCI, as it rolls up from its -100 signal line;
2 - Overlapping of Slow STO's signal line;
3 - Tapering of ADX's +DI line at 15 and up-turn of ADX line.

A shorter timeframe in the DAILY Chart #2 maintains similar bullish reversal signs in positive divergence formations, oversold positions and trendline behaviors, especially regarding the recent close's position relative to the lower border of the bearish channel.

A in-between view (relative to the monthly and daily views) provided in the WEEKLY Chart #3 below provides yet again similar technical indications that $USD is very likely to rally - Most notably a modest "pincher formation" between PPO and ADX, as well as a rising Slow STO towards its signal line, and a close so far this week at the lowest historical weekly support line (bottom of bullish channel drawn last year in NOV 2008).

Lastly, I am posting a relative strength Chart #4 between directionally opposite funds (UUP vs. UDN, directionally bullish and bearish PowerShare Fund, respectively), where their relative strength positions coincides with $USD's bullish technical outlook above. However, most technically relevant event is the recent violation of a significant trendline (blue dashed line) and persistent validation from then resistance to now support line.

Overall - These signals are early, but discreetly line up for a probability of a rally, IMHO:

Chart #1: $USD - 10-Year Monthly Chart:



Chart #2: $USD - 12-Month, Daily Chart:



Chart #3: $USD - 36-Month, Weekly Chart:



Chart #4: PS Index Bullish/Bearish Fund - 12-Mo., Daily Chart:


- Dalcindo

[dalcindo]

Re: ARNA - TYPO CORRECTION

Should have said: Resistance @ $3.80's - corresponding to Fib's 23.6% rally since decline; RSI on the rise, while secondary indicators are also turning up:

ARNA - 2-Month, 60-Minute Chart:


- Dalcindo

[dalcindo]

Re: ARNA - TYPO CORRECTION

Should have said: Resistance @ $3.80's - corresponding to Fib's 23.6% rally since decline; RSI on the rise, while secondary indicators are also turning up:

ARNA - 2-Month, 60-Minute Chart:


- Dalcindo

[dalcindo]

Re: ARNA

Hi, RTN! How have you been?

Can you get it now?

Original entry:

------------------------
Re: ARNA - Watch for ARNA breaking resistance:

Resistance @ $3.60's - corresponding to Fib's 23.6% rally since decline; RSI on the rise, while secondary indicators are also turning up:
------------------------


ARNA - 2-Month, 60-Minute Chart:



Message In Reply To:
heh.. only now see your posting

entered 3,54


http://investorshub.advfn.com/boards/read_msg.aspx?message_id=43411543

can you load that chart?

[read_this_n0w]

heh.. only now see your posting

entered 3,54


http://investorshub.advfn.com/boards/read_msg.aspx?message_id=43411543

can you load that chart?

[dalcindo]

Re: ARNA - Watch for ARNA breaking resistance:

Resistance @ $3.60's - corresponding to Fib's 23.6% rally since decline; RSI on the rise, while secondary indicators are also turning up:

ARNA - 2-Month, 60-Minute Chart:


- Dalcindo

[dalcindo]

Article, Re: NVAX


Source: http://finance.yahoo.com/news/Novavax-Begins-Phase-IIa-prnews-1996428838.html?x=0&.v=1


Novavax Begins Phase IIa Study of Seasonal Influenza Vaccine in Older Adults
-- Dose-ranging study in older adults compares Novavax's trivalent virus-like-particle (VLP) vaccine to currently marketed flu vaccine, Fluzone(R)

* Press Release
* Source: Novavax, Inc.
* On 8:00 am EST, Tuesday November 10, 2009

ROCKVILLE, Md., Nov. 10 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX - News) has begun a Phase IIa clinical study of its trivalent seasonal influenza VLP vaccine candidate in healthy adults 60 years of age or older. This randomized, double-blind, active-controlled study is evaluating the safety, tolerability and immunogenicity of two different doses of Novavax's trivalent seasonal influenza VLP vaccine compared with that of a commercially available trivalent inactivated vaccine (TIV, Fluzone®). Novavax's vaccine contains VLPs made up of the hemagglutinin (HA), neuraminidase (NA), and matrix 1 (M1) proteins against the H3N2, H1N1, and B strains recommended for 2009-2010 influenza vaccines.

"This is a very important study because it will help establish the safety and immunogenicity of our trivalent seasonal influenza VLP vaccine in older adults and allow us to select a dose for a future Phase IIb confirmatory, non-inferiority clinical trial in this population. Moreover, it will also give us a clear signal of how our seasonal influenza VLP vaccine compares to the current standard of care, TIV (Fluzone®)," said Dr. Rahul Singhvi, President and Chief Executive Officer of Novavax. "Recall that in a recent Phase II study in healthy adults ranging in ages from 18-49 years, we showed that our seasonal influenza VLP vaccine was safe and immunogenic at 15 and 60 mcg dose levels. These data give us great confidence as we move forward in this current clinical trial in older adults."

The current trial is a Phase IIa randomized, double-blind, active-controlled study to evaluate the safety, tolerability and immunogenicity of the trivalent seasonal influenza VLP at 15 mcg and 60 mcg per strain in healthy adults who are 60 years of age or older. The safety and immunogenicity of the influenza VLP vaccine at these two dose levels will also be compared with that of a commercially available inactivated trivalent seasonal influenza vaccine, TIV (Fluzone®), administered at the standard dose of 15 mcg of HA per strain. A total of 480 subjects will be enrolled, in a 1:1:1 randomization schedule (160 subjects in each of the three arms) at approximately six sites in the United States and one site in India. In addition to evaluating hemagglutinin inhibition (HAI) responses, anti-neuraminidase and cell-mediated immune responses will also be examined. Preclinical studies have shown that influenza VLP vaccines drive stronger T-cell responses than TIV (Fluzone®), indicating the potential for better immunologic responses in clinical trials particularly in older adults.

Seasonal Influenza

Seasonal influenza infects between 5 percent and 20 percent of the world's population and kills between 250,000 and 500,000 people each year. In the United States, the Centers for Disease Control and Prevention estimates that 15 to 60 million people contract influenza each year leading to over 200,000 hospitalizations and 36,000 deaths. The Advisory Committee on Immunization Practices ("ACIP") currently recommends seasonal influenza vaccination for children six months through 18 years of age, pregnant women, and adults over 50 years of age, and individuals of any age with chronic health conditions or who are at high risk of influenza disease. Based on the expanding recommendation of vaccination to new age groups, the growing worldwide population to be vaccinated, and the need of an improved influenza vaccine for the elderly, global market projections of seasonal influenza are estimated to increase from $2.8 billion in 2007 to $6.5 billion by 2013.

About VLPs

Virus-like particles (VLPs) mimic the external structure of viruses but lack the live genetic material that causes viral replication and infection. VLPs can be designed quickly to match individual viral strains and be produced efficiently using portable cell-culture technology. Novavax's VLP-based vaccine candidates are produced more rapidly than egg-based vaccines by using proprietary, portable, recombinant cell-culture technology.

About Novavax

Novavax, Inc. is a clinical-stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP-based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The Company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: www.novavax.com.

Forward-Looking Statements

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding clinical trials and development of the seasonal influenza vaccine and other anticipated milestones are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including clinical trial results, which may not be sufficient for regulatory approval or may indicate safety concerns not yet encountered; even if the results of the planned clinical trials are positive, the data may not be accepted by regulatory bodies or the seasonal influenza vaccine may not be approved by the United States government or additional clinical trials may be required; the Company has not yet manufactured, or relied on third parties to manufacture, any vaccines at a commercial scale; competition from already approved vaccines for seasonal influenza; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; the Company's ability to obtain rights to technology; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; the Company's ability to enter into future collaborations with industry partners and the terms, timing and success of any such collaboration; the cost, timing and success of regulatory filings and approvals; the Company's ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity or debt financing or otherwise; general business conditions; competition; business abilities and judgment of personnel; and the availability of qualified personnel. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.

Copyright © 2009 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
---------------------------------------------------------------

- Dalcindo

[dalcindo]

FYI: HENC - 36-Month, Weekly view (advertised on StockWire.com):

HENC has been advertised by StockWire.com (SW.com), which had provided reliable fundamental-based promotions in the past.



- Dalcindo

[dalcindo]

Weekly Scans - Week of 09 NOV 09:

Not as bad as last week, but this is getting pretty thin still - Here is only one stock resulting from the three scans:

Bucking Bull:
Count: 0

Bull Pop:
VOIS VOIS Inc. NASD
Count: 1

ROW x STO:
VOIS VOIS Inc. NASD
Count: 1

Happy trading week!

- Dalcindo

[dalcindo]

Re: UNG - Weekly, daily, 60-minute Charts:

Hi, The Profit Taker!

I added $UNG on stockcharts.com's public list seveeral months ago ... You are welcome to look at the weekly, daily and 60-minute views (see below and this link: http://stockcharts.com/def/servlet/Favorites.CServlet?obj=ID2140281 )at your leisure.

Technically speaking, it seems that each timeframe remains still predominantly bearish.

The 36-month, weekly has all the features of a bearish stock for now. The RSI double-topped at/below 40-level recently corresponding to severe resistance at about $12.22. All secondary indicators also remain bearish in this weekly view, where ADX gives impetus to its (-)DI, and institutional interest remains on the sell side.

The 12-month, daily view may indicate some weak positive divergences, but the directional trend remains predominantly bearish. Some faint positive divergences are seen in the CCI, but it fails to provide a buy signal as it squats persistantly < -100. At the time of this writing, the only institutional trend reversal (i.e.: breaking over its 21-EMA line) is the ChiOs, which may reflect speculative players (i.e.: MM's), rather than retail or registered shareholders, whose trends remain on the sell side (using Mary Kay Austin "MKA" interpretation of OBV, A/D line and ChiOs).

The 2-month, 60-minute chart is making the case for the most recent and predominant directional trends: bearish. Looking at the price's 5,9,21-EMA's in this 60-minute timeframe, they have remained lined-up bearishly, where the 9-EMA has provided the most frequent resistance, followed by the 21-EMA. Until these lines remain bearishly reversed, the outlook remains predominantly bearish (assuming that this 60-minute timeframe would provide the earliest inkling of a reversal trend, which would still remain to be proven on a daily chart, IMHO).

OVERALL - Bearish, IMHO.




UNG - 36-Mo., Weekly Chart:



UNG - 12-Mo., Daily



UNG - 2-Mo., 60-Min. Chart:


As indicated above, these charts are publicly listed on this list:
http://stockcharts.com/def/servlet/Favorites.CServlet?obj=ID2140281

- Dalcindo

[dalcindo]

Alert - STSI; Potential breakout

Risky option play, but great ascending formation ...

- Dalcindo

[dalcindo]

Weekly Scans - Week of 02 NOV 09:

Although there are NO detectable bull scans for this week, it is still worth noting that last time this occurred, we were entering a historical bear market ... This zero-result might still be good for something in the way of signaling another significant event, may be?

Bucking Bull:
Count: 0

Bull Pop:
Count: 0

ROW x STO:
Count: 0

- Dalcindo

[dalcindo]

$COMPQ and BDH: QCOM, GMW, MOT - TOP 3 Broad Band ETF Holders:

Looking at BDH's chart (upper chart portion) and its singled lines of top 3 holdings (lower chart portion: Qualcomm, Corning and Motorola), the bearish trend is becoming pretty obvious.

Most marking is the directional "conversion" of BDH from its earlier bullish to its recent bearish channel validation:

The recent bearish crossing of 20-daily and 50-daily EMA's that occurred in early OCT may signal an early bearish reversal.

As mentioned several times in the past about weakening US demographics in terms of consumer force, this chart may represent an early validation that the market lacks the credit and demand boosting power to sustain this BDH's related companies. This point may become more apparent into 2010, but let's keep on following this trend for now with this and the next $COMPQ chart.

Note in the second $COMPQ daily chart below how discreet bearish trends in RSI, MACD and TRIN are breaking their respective support/resistance lines.

OVERALL - If you check other broad indices and their relative positions within channels, it may become obvious that we are entering another bearish phase - Check out my public list in the second and third page for a reversal confirmation in $SPX's SML and MID charts ... It's getting pretty bearish, IMHO:

BDH - Top 3 Holdings - 12-Month, Daily Chart:




$COMPQ - 36-Month, Daily Chart:


Check out the weekly and monthly $COMPQ and other broad indices and see how the bearish trend is gaining strength: http://stockcharts.com/def/servlet/Favorites.CServlet?obj=ID2140281

- Dalcindo

[dalcindo]

Re: PDMI

Hi, Xxx!

Agreed - Looks like PDMI is getting strong support at current levels. Understandably, this is a pinkie, so not much to expect from it in terms of guarantee or consistency, but so far, it has good technicals:

1 - RSI holds above the daily 50-line;
2 - Price recently "converted" from bearish channel validation to bullish channel validation;
3 - CCI, Wm%R and CMF are lining up into pre-rally set-up;
4 - Institutional interest is burgeoning once more.

OVERALL - BULLISH outlook.

PDMI - 12-Month, Daily Chart:


- Dalcindo

----------------------------------------------------------------

Private Message In Reply To:
PDMI looks real close back to a buy point off the 50 sma. bounce.
----------------------------------------------------------------

D.

[dalcindo]

Re: ACLS - Bouncing; Remains Bullish

Looking at this 12-month, daily chart, there are ample technical indications that the recent decline was corrective, rather than bearishly directional:

1 - RSI has remained in its 40-80 bullish range and has since bounced off of its bullish historical trendline;
2 - The price has moved steadily within its bullish channel; while its 200-daily EMA should hold, I can see it test the bullish channel's midline shortly;
3 - Secondary indicators are lined up to reinforce this bullish sentiment, although the institutional support is yet premature, but did start to roll up as of two trading days ago.

OVERALL - This chart offers a nice array of bullish continuation following a short corrective decline.

I do hold a CALL option position in ACLS

ACLS - 12-Month, Daily Chart:


More technical charting from this technical junkie here:
http://stockcharts.com/def/servlet/Favorites.CServlet?obj=ID2140281

- Dalcindo

[dalcindo]

Re: CSCO - BEARISH: Weakness At Major Resistance:

(see same technical comments in chart:
27 OCT 09 - TECH-NOTE:
Watch for early reversal signs developing along this blue line
- RSI rallies, but fails 70-line
- Price butts head at important historical line
- Secondary indicators are pulled taut to the overbought side; negative divergences are developing):

CSCO - 60-Month, Weekly Chart:


This chart is publicly listed on this list:
http://stockcharts.com/def/servlet/Favorites.CServlet?obj=ID2140281

- Dalcindo

[dalcindo]

Re: $USD - PowerShare's USD Bullish vs. Bearish Funds

$USD - PowerShare's USD Bullish vs. Bearish Funds:
Here, for a somewhat abstracted view of the relative strength between conflicting positions in the $USD, check out this comparative chart that pits bulls against bears.

Note how volume spikes have buoyed USD above its 21-daily EMA, how RSI tests its historical resistance line, and price is bouncing off of its bearich channel lower border - Things are lining up nicely for a definite rally, IMHO:



This chart is publicly listed on this list:
http://stockcharts.com/def/servlet/Favorites.CServlet?obj=ID2140281

- Dalcindo

[dalcindo]

Re: $USD - 36-Month, Daily Chart:

As indicated last time (see link above), $USD is nearing several technical points from which to bounce. Expect some major gain the the Dollar over the next few weeks, IMHO (Currently SHORTING the EUR:USD pair):

$USD - 36-Month, Daily Chart:


This chart is publicly listed on this list:
http://stockcharts.com/def/servlet/Favorites.CServlet?obj=ID2140281

- Dalcindo

[dalcindo]

Weekly Scans - Week of 26 OCT 09:

Bucking Bull:
ACPW Active Power, Inc. NASD
EXXI Energy XXI Ltd. NASD
JADE LJ Intl, Inc. NASD
JOEZ Joe's Jeans Inc. NASD
MCZ Mad Catz Interactive, Inc. AMEX
MPET Magellan Petroleum Corp. NASD
Count: 6

Bull Pop:
GBE Grubb & Ellis Co. NYSE
Count: 1

ROW x STO:
CIRC CirTran Corp. NASD
GBE Grubb & Ellis Co. NYSE
GZGT GuangZhou Global Telecom, Inc. NASD
Count: 3

- Dalcindo

[dalcindo]

Re: ARNA

Fibs holding right at 200-EMA, so pretty solid support at the current $4.40 level.

Significant resistance levels may be reliably identified by this chart's subsequent Fib levels, IMHO:

2-Month, 60-Minute Chart:


D.

[dalcindo]

Re: ARNA option

Very nice indeed. I actually got into a OOM lotto position with UGGKA at 30.

Just increased to 35 (ARNA Nov 5 Call).

Indeed, expecting a bit more out of this turnip.

D.

[read_this_n0w]

Nice chart D.

ARNA options avg price .52 for the nov 4$ calls
bid today .70.75 for those options

thats not bad for so short timeframe,
expect more

realtime price 4,48

[dalcindo]

Re: ARNA - 2-Month, 60-Minute Chart:

Hi, RTN!

Here is a 2-Month, 60-Minute Chart revealing significant Fibonacci levels. So, it seems that traders within this 60-minute timeframe remain in control with some predictable technical patterns.

See how each Fib levels correspond significantly well with historical support and resistance levels.

Will keep an eye on it. Let me know if any significant moves are going on.

Significant moves should include:
1 - $4.75 resistance violation
2 - Closest Fib resistance level.

Thank you.



- Dalcindo

[dalcindo]

Re: ARNA

PRO's:
- There seems to be a renewed institutional interest among MM's, registered shareholders and retailers (using MKA's interpretive method); so lots of renewed buying pressure here.

CON's:
- 4.37 sound-barrier remains in effect per 15-minute chart.
- A 60-minute chart signals bearish hurdle in RSI, which failed to cross over its 60-level.

Overall - Pretty strong resistance at 4.37. Once this hurdles breaks, it should provide a good support going forward. Once the product gets some positive note, then one should see this fly, IMHO.

- Dalcindo

[read_this_n0w]

ARNA nov 4$ calls interesting here, bought

obesitas congress next week

[dalcindo]

Article - Weak Dollar? Not So Much in China

by Floyd Norris

Friday, October 16, 2009

provided by The New York Times



There is renewed talk about the weak dollar. But don’t believe it.

Where it really counts, the dollar is not moving at all.

In February, the dollar hit a high against most currencies amid fears of worldwide recession and a desire for the safety of American investments. It was then worth 80 euro cents, and 6.82 Chinese renminbi.

This week, as the dollar neared 67 euro cents, it was still worth 6.82 renminbi.

If you are good in arithmetic, you will immediately realize that the euro has been rising against the Chinese currency. And so has the Japanese yen, the British pound and most every other currency you have heard of.

The strongest and most resilient economy in the worldwide recession has one of the weakest currencies.

In a normal world, that would be a puzzler. As it is, it is simply a problem that governments prefer to ignore.

To be sure, there are some currencies that have been significantly weaker than the Chinese renminbi since February. Searching Bloomberg’s database, I found seven: the Argentine peso, the Icelandic krona, the Costa Rican colon, the Pakistani rupee, the Nigerian naira, the Vietnamese dong and the Iranian rial.

That is not a list of countries whose economies anyone would be eager to emulate.

The reason for this is simple, and obvious. China pegs its currency to the United States dollar.

You may remember that peg was very controversial a few years ago. After much griping from the United States and Europe, in 2005 China decided to allow its currency to gradually appreciate against the dollar. But that policy was reversed in the summer of 2008, and since then the Chinese currency has been flat against the dollar.

China talked at the time of using a basket of currencies, rather than the dollar, and letting its currency appreciate against the basket. But the result this year has made it clear that there is no basket, unless perhaps it is made up of the naira, the dong and the rial.

There has been some carping about China’s foreign currency policy in Europe, with Jean-Claude Trichet, the president of the European Central Bank, talking about the need for some currencies in emerging markets to appreciate.

But most Western officials would rather talk about something else.

In a statement earlier this month, finance ministers from the Group of 7 did have something to say about China: “We welcome China’s continued commitment to a more flexible exchange rate, which should lead to continued appreciation of the renminbi in effective terms and help promote more balanced growth in China and in the world economy.”

That statement came about 15 months after China halted “the continued appreciation of the renminbi,” a fact the ministers chose not to mention.

Currency diplomacy has never been an area where frank speaking was deemed admirable. Back in the days of fixed exchange rates, when countries were sometimes forced by crises to make abrupt changes, there was even a saying: “He lied like a finance minister on the eve of devaluation.”

This year, Treasury Secretary Timothy F. Geithner was widely viewed as having committed a diplomatic faux pas during his confirmation process when he said President Obama believed China was manipulating its currency. The Treasury has since managed to avoid concluding that was happening.

For its part, China has been critical of the United States for its fiscal and trade imbalances, without mentioning that those imbalances have been exacerbated by China’s own policies.

“To rant and rave about the unsustainability of our fiscal policy when they have their own unsustainable monetary policy is a classic case of the pot calling the kettle black,” said Robert Barbera, the chief economist of ITG.

“I still think,” he added, “that the single most destabilizing decision of the last 10 years was the Chinese peg.”

That peg forced China to take in huge quantities of dollars and then invest them in dollar-denominated securities, principally Treasuries. That in turn helped to hold down American interest rates and stimulate the housing boom that has since collapsed.

These days it seems to be in the short-term interests of both countries for China to pursue its current policy. The Americans desperately want someone to buy all the Treasuries that are being issued to finance the stimulus program and bank bailouts, and China wants to do whatever it can to stimulate its own economy.

As David Barboza reported in The New York Times this week, some Chinese exporters have been reducing pay to hold down prices and continue making sales to the United States. A stronger currency would make such sales even more difficult to make.

Such considerations have led some to argue that China’s peg is a stabilizing force in the world economy. But that makes no sense, at least in the long run. “Something that is inherently unsustainable can’t be a force for stability,” said Jon Faust, an economic professor at Johns Hopkins University.

It is hard to see how China will do well with all those low-yielding Treasury investments, simply because it is difficult to imagine that, someday, the renminbi will not rise against the dollar. Unless, that is, China’s own monetary policies unleash a wave of inflation in that country that reduces the international value of the currency.

But while China pursues its peg, the world’s largest exporter will keep exporting and taking in cash rather than imports. The values of the major international currencies will fluctuate against each other, but the inherently stabilizing impact of changing currency values will be limited.

One lesson of the credit boom in the United States was that things that are unsustainable will eventually stop, perhaps abruptly and in highly disruptive ways. The same may yet be said of China’s peg.

Floyd Norris comments on finance and economics in his blog at nytimes.com/norris.

-------------------------------------------------------------

- Dalcindo

[dalcindo]

Re: $XAU vs. $USD - 10-Year, Monthly Chart:

Note how gold is nearing the upper border of its bullish channel. While prior chart indicated an imminent rally in the $USD (see link above), the current technical position of gold - which is often inversely paired to the dollar - seems to indicate a same, but opposite likely reactive move.

OVERALL - As gold and the dollar remain inversely lock-stepped, this chart points to a likely rally in the $USD:



This and prior charts can be found here: http://stockcharts.com/def/servlet/Favorites.CServlet?obj=ID2140281

Thanks.

- Dalcindo

[dalcindo]

Re: $USD - 10-Year, monthly Chart:

I am expecting the USD to rebound from the bottom of that bullish channel. While Slow STO is preparing to signal an imminent rally, CCI and ADX look taut in their current overbought positions.

OVERALL: Some relaxation to the upside is expected:



- Dalcindo

[JUST 10-11-12]

IWEB one on your scans....

low floater!
nice chart!
volume!
13 cents is blue skies!

conference next week;
new product being unveiled;


any imput/projections(30 cents; 50 cents)

thank you!

Keith

[dalcindo]

Re: BIDU

As indicated in prior analysis, BIDU declined significantly. Good job to you if you shorted this stock!



- Dalcindo

[dalcindo]

Weekly Scans - Week of 19 OCT 09:

Bucking Bull:
ICO International Coal Group, Inc. NYSE
LAVA Magma Design Automation Inc. NASD
NSU Nevsun Resources Ltd. AMEX
UEC Uranium Energy Corp. AMEX
VGZ Vista Gold Corp. AMEX
Count: 5

Bull Pop:
AIS Antares Pharmaceutical, Inc. AMEX
MCZ Mad Catz Interactive, Inc. AMEX
URGP Urigen Pharmaceuticals Inc. NASD
Count: 3

ROW x STO:
AIS Antares Pharmaceutical, Inc. AMEX
IWEB IceWEB, Inc. NASD
Count: 2

- Dalcindo

[JUST 10-11-12]

it has been hanging onto the 10dma!

expecting an uplisted to a major exchange this fall.
so, the position should pop!

Keith